Ozanimod is an oral selective sphingosine-1-phosphate (S1P) receptor modulator primarily used for the treatment of multiple sclerosis (MS) and ulcerative colitis (UC). It exerts immune regulatory effects by inhibiting the migration of lymphocytes from lymph nodes and reducing the number of lymphocytes in peripheral blood.

The therapeutic effect of multiple sclerosis

In phase III clinical trials of relapsing remitting multiple sclerosis (RRMS), Ozamod has shown significant efficacy. Compared with interferon beta-1a, daily administration of 0.92mg of Ozamod can reduce the annual recurrence rate by 48% and decrease the number of new or enlarged T2 lesions detected by MRI by 63%.

2. Treatment effect of ulcerative colitis

For moderate to severe active ulcerative colitis, Ozamod has shown good efficacy in both induction and maintenance therapy. The clinical remission rate reaches 18-37% during the induction period and 41% during the maintenance period. The secondary endpoints of endoscopic improvement and histological remission were also significantly better than those of the placebo group.

3 Safety Performance

Ozamod has good overall tolerance, and common adverse reactions include headache, upper respiratory tract infection, and elevated liver enzymes. Due to its impact on heart rate, dose escalation and monitoring are required for the first administration. Compared with other S1P receptor modulators, the effect of Ozamod on lung function and lymphocyte recovery is relatively small.

4 Special advantages

Ozamod has high selectivity for S1P1 and S1P5 receptors, with minimal impact on S1P3 receptors, which may be the reason for its fewer cardiovascular side effects. In addition, its metabolite CC112273 also has pharmacological activity and can prolong the duration of drug action.